

A

- Acquired immune deficiency syndrome (AIDS), 9, 16, 53, 125, 249, 250
 - AGMs and, 269
 - chimpanzees and, 263–264
 - f*[δ]32 and, 38
 - FAIDS and, 126, 145 *table*, 146, 147, 148
 - HLA polymorphism and, 300
 - HTLV and, 166
 - macaques in research, 251
 - progression to, 221, 282, 289, 290, 301–303
 - sooty mangabeys and, 256
- Adaptor proteins (APs), 111
- Adult T-cell leukemia (ATL), 159, 164, 165
- African green monkeys (AGMs), 5–6, 8, 249, 266, 269, *see also* SIVagm
- AIDS-related complex (ARC), 148
- AMD3100, 44
- Antibodies, 284, 285
 - neutralization, 16, 17, 137, 138, 191–203, 254, 255, 269, 285
- Antibody-dependent cell-mediated cytotoxicity (ADCC), 266
- Antigens, *see also* Human leukocyte antigens (HLAs)
 - presentation and recognition, 213, 214
- Antiretroviral therapy, 317
 - CTL responses and, 222–224
- Antiviral therapy
 - T-helper cells and, 242

B

- Bicyclins, 44
- Bisexuality, 15
- B lymphocytes, 85, 196
 - feline, 147, 148
 - murine, 131, 133, 134, 137, 140
- Bone marrow (BM)-derived inocula, 91, 92
- Bovine leukemia virus (BLV), 159

C

- Calcium channels, 115, 116
- Cameroon, 2, 13
- Cats, *see headings beginning Feline*
- CCR2-V641, 39, 40

- CCR3, 36, 61, 62, 65
- CCR5, 9, 10, 35, 36, 43, 44, 61, 65, 114, 115, 192–194
 - CCR5 59029 A/G, 39, 40
 - CCR5 δ 32, 37–39, 42, 62
 - CCR5 m303, 39, 40
 - CCR8, 65
 - CD3⁺, 83, 84, 91–92
 - CD4, 9, 35–37, 317–320
 - downregulation of, 83, 84, 109–111
 - CD4⁺
 - in FAIDS, 146–148
 - in FIV, 147, 148
 - in FV, 137
 - in HIV, 35, 43, 53, 55, 60, 93, 114
 - in HTLV, 162
 - SIV and, 252, 253, 254, 257, 258, 261, 262, 265
 - CD8, 84, 238
 - CD8⁺
 - in FIV, 137, 147, 148
 - in FV, 137
 - in HAM/TSP, 169, 170, 171–174
 - in HIV, 56, 61, 88, 93
 - in late HIV disease, 222
 - in MAIDS, 131, 133
 - in PI, 217–220
 - SIV and, 252, 253, 257, 258, 260–262, 264, 265
 - CD30, 55
 - CD34, 80–82
 - CD34⁺, 81, 82
 - CD38, 81
 - CD45, 87
 - CD95, 55
 - Central African Republic, 1, 11
 - Cercocebus torquatus atys*, *see* Sooty mangabeys
 - Chemokine receptors, 9, 60–65
 - cytokines and, 64
 - disease progression and, 37–40
 - HIV-1 entry and, 36, 37, 40–42
 - HIV-1 tropism and, 35, 36

- in SIVsm, 257
- in sooty mangabeys, 257
- structure, 34
- Chemokines
 - CC, 34
 - families, 34
 - function, 34, 35
 - MCP, 113, 114
 - signaling, 34, 35
 - structure, 33, 34
 - therapeutic implications, 42–44
- Chemotaxis, 113, 114
- Chemotherapy, *see* Therapy
- Children, thymic function in, 92, 93
- Chimpanzees, 2, 198, 250
 - AIDS and, 263, 264
 - apoptosis and, 265, 266
 - HIV-1 and, 262, 263
 - humoral responses in, 266
 - immunodeficiency and, 263–266
 - lentiviruses and, 263
- Chlorocebus*, 266, *see also* African green monkeys (AGMs)
- Circulating recombinant form (CRF), 8
- Corticosteroids, 321
- CPZANT, 2, 3
- CPZGAB, 2
- CPZUS, 2, 3
- CRF AB (KAL153), 8
- CRF AE (CM240), 8, 11
- CRF AG (IbNg), 8
- CXCR4, 9, 10, 36, 41, 61, 65, 114, 115, 116, 147, 192–194
- Cytokines
 - chemokines and, 64
 - cocktails, 65, 66
 - HAM/TSP and, 168, 169, 175, 176
 - inflammatory, 56, 57
 - in MAIDS, 133, 134
 - measurement of, 54
 - MMTV and, 142
 - pro- and antiinflammatory, 58–60
 - pro-inflammatory, 54–56, 320–322
 - SIV and, 261, 262
 - stromal cells and, 85–87
 - Th1-related, 57
 - therapies based on, 318–320
- Cytolytic T lymphocytes (CTLs), 15–17, 115, 197, 237, 238, 285
 - epitopes, 18–21
 - HCV and, 242
 - HLA class I and, 306–312
 - SIV-specific, 252, 253, 255, 256, 260, 261
 - T-helper cell responses and, 241, 243–244
- Cytomegalovirus (CMV), 237
- Cytotoxic T lymphocytes (CTLs), 65, 213
 - antiretroviral therapy and, 222–224
 - effector functions, 214–216
 - escape mechanisms, 216, 217
 - in FIV, 136, 137, 149
 - in HAM/TSP, 170–174
 - HLA class I and, 306–312
 - in MMTV, 142
 - in M-MuLV, 138, 139
 - in PI, 217–221
 - in progressive HIV infection, 221, 222
- D**
 - δ32, *see* CCR5δ32
 - Djibouti, 13
 - Double positive (DP) cells, 83–85
 - Duplan-Laterjet strain, 131
- E**
 - Env proteins, 58, 116, 240
 - in MuLV, 136
 - neutralizing antibodies and, 191, 198, 199, 201
 - oligomeric, 201
 - SHIV and, 198
 - Epidemics, 1, 2
 - Epidemiology
 - HIV, 1, 2
 - HIV-I, 11–15, 300–306, 307
 - HTLV-I, 163
 - HTLV-II, 163
 - Epitopes
 - CTL, 18–21
 - mutation, 217
 - Epstein-Barr virus (EBV), 237
 - Exposed-uninfected (EU) individuals, 37, 39, 42, 62
- F**
 - Family studies, 300
 - Feline acquired immune deficiency syndrome (FAIDS), 125, 126, 132 *table*, 144–148
 - Feline immunodeficiency virus (FIV), 125, 144, 146, 147–149
 - Feline leukemia virus (FeLV), 125, 144, 146
 - FeLV FAIDS, 145, 146

Fetal thymic organ culture (FTOC), 83, 84
 Fluorescence-activated cell sorter (FACS), 54
 Fractalkine, 34
 Friend murine leukemia virus (FMuLV),
 135–137, *see also* Murine leukemia
 virus (MuLV)
 Friend virus complex (FV), 132 *table*, 135–138
 Fusin, 35–36, 61, *see also* CXCR4

G

Gag proteins, 240
 Gambian prostitutes, 16
 Gene therapy, 43, 44
 Glycosylation, 17
 gp41, 36, 191, 195, 196, 201, 202
 gp120, 18, 36, 37, 58, 191, 192, 195, 196, 199,
 201, 202
 gp120 V3 domain, 284–288
 gp140, 201
 gp160, 199, 322, 323
 G protein-coupled receptors (GPCRs), 34, 35
 G protein receptor kinases (GRKs), 35
 Granulocyte-colony stimulating factor
 (G-CSF), 319
 Grivet monkeys, *see* African green monkeys
 (AGMs)

H

Hairy cell leukemia, 159
 Helper T-cells, *see* T-helper (Th) cells
 Hematopoietic stem cells (HSCs), 80, 81
 Hemophilia, 300, 301
 Heparan sulfate, 41
 Heparin, 41
 Hepatitis C virus (HCV), 242
 Heterosexuality, 9, 11, 13, 15
 Highly active antiretroviral therapy
 (HAART), 53, 79, 96, 97, 114, 222–224,
 243, 311, 312, 323, *see also* Therapy

HIV

chemokines in, 60–65
 chronic infection, 221, 222
 CTL responses in, 221, 222
 cytokines in, 53–60
 decreasing replication, 320–325
 epidemiology, 1, 6, 11–15, 53
 genetic aspects, 300, 301
 HLA polymorphism and infection, 300–311
 infection, 53, *see also* Primary HIV
 infection (PI)

lentiviruses and, 2–6
 neutralizing antibodies and, 196–198
 pharmacological approach, 65, 66
 primate lentiviruses and, 2–6
 progressive infection, 221, 222
 Th1-related cytokines in, 57
 T-helper cells in, 239–244
 variability, 1, 306

HIV-1

antibody-mediated neutralization, 191–203
 chemokines and, 33, 36–42
 chimpanzees and, 262, 263
 diversity within, 2
 entry into target cells, 36, 37, 40–42
 epidemiology, 11, 13–15, 300–306, 307
 evolution of phenotype, 283, 284
 genetic variation, 10, 11
 groups, 2, 3, 5, 6, 11
 heterogeneity of, 281–290
 immunology, 15–22
 intersubtype recombination, 7–9, 13, 14
 intrahost evolution, 281–290
 model of continuous virus adaptation,
 288–290
 molecular epidemiology and, 11–15
 neutralizing antibodies and, 191–203
 nonsynonymous *vs.* synonymous
 substitutions in, 286–288
 progression of, 281–290
 receptors, 35, 36
 subtypes, 6–7, 9–15
 T-helper cells, 237–244
 thymic function in, 92–97
 thymic mass in, 94–97
 transmission, 11, 13, 15, 282, 283, 301
 tropism, 35
 vaccine design and subtypes, 18–22
 virus loads, 198, 282

HIV-2

mortality due to, 9
 subtypes, 5

Hodgkin's disease, 93

Homosexuality, 11, 13–15, 301

HTLV-I

AIDS and, 166
 associated diseases, 164–166
 epidemiology, 163
 genetic structure, 159–161
 HIV progression and, 166
 seropositivity, 164
 transformation of, 162
 transmission of, 161, 162

- HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP), 159, 162, 166
 autoimmune hypothesis, 176
 clinical features, 165
 CTL responses in, 170–174
 cytotoxic hypothesis, 175, 176
 host susceptibility to, 167
 immune dysregulation in, 169, 170
 immunopathogenesis of, 167–176
 neuropathology of, 168, 169
 T-cell receptor usage in, 174, 175
 viral load in, 167, 168
- HTLV-II, 159
 AIDS and, 166
 associated diseases, 166
 epidemiology, 163
 genetic structure, 159–161
 HIV progression and, 166
 seropositivity, 164
 transformation of, 162
 transmission of, 162
- Human leukocyte antigens (HLAs), 16
 class I, 297–299, 301–310, 312
 class II, 299, 305, 310–312
 CTLs and, 306–312
 gene polymorphism in, 299, 300
 genes in, 297
 HAM/TSP and, 167
 zygosity and, 301, 302
- I**
- IgG1b12, 18
 IL-12a, 56
 Immunotherapy, 322–325
 Injecting drug users, 15, 163, 301
 Interferon- (IFN-), 56, 57
 Interferon- γ (IFN- γ), 54–57, 59, 239
 Interleukin-1 β (IL-1 β), 54, 58
 Interleukin-2 (IL-2), 65, 112, 115, 173, 318, 319
 Interleukin-4 (IL-4), 173, 319, 320
 Interleukin-6 (IL-6), 54, 59
 Interleukin-7 (IL-7), 85, 86
 Interleukin-10 (IL-10), 56, 59, 60, 321, 322
 Interleukin- κ B (IL- κ B), 58
- J, K**
- Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, 58
 Jurkat T-lymphoid cells, 112
- Kaliningrad, 1
 Korea, 11, 13
- L**
- Lentiviruses
 chimpanzees and, 263
 HIV and, 2–6
- Leukemia
 adult T-cell, 159
 hairy cell, 159
- Long-term non-progressors (LTNP), 198, 217
 LP-BM5 MuLV, 131, 133
- Lymph node (LN)-derived inocula, 91–92
- Lymphocytes
 “adolescent,” 87, 88
 adoptive transfer of, 320
 effector, 89, 90
 homeostasis, 91–97
 memory, 88, 89, 243
 naïve, 87–89, 243
 ontogeny, 80–90
 in SIVmac, 252
 in SIVsm, 257, 258
 in therapy, 320
 thymus-derived *vs.* peripheral expansion, 91, 92
- Lymphocytic choriomeningitis virus (LCMV) model, 238
- Lymphopenia, 94
 Lymphotactin, 33, 34
- M**
- Macaca mulatta*, *see* Macaques
 Macaques, 112, 198, 240, 250–256, 258 *table*, *see also* SIVmac
 immune responses in, 252–254
 PI in, 220
 protective immunity in, 254–256
- Macrophage-derived chemokine (MDC), 63, 64
- Major histocompatibility complex (MHC), 127, 131, 213, 214
 downregulation of, 109–111, 115
 “Marilyn” (chimpanzee), 2
- Memory, immunologic, 88, 89
- Mice, *see also headings beginning Murine*
 knockout, 86
 retroviruses, 128 *table*
 SCID, 139, 199, 221
 transgenic (tg), 111, 112
- Mink cell focus-inducing viruses (MCV), 127

MIP-1 α , 42
 MIP-1 β , 42
 MMTV SAGs, 140–142
 Molecular epidemiology, 11–15
 Moloney murine leukemia virus (MMuLV),
 138, 139
 Monoclonal antibodies, 18
 Monocyte chemotactic protein (MCP)
 chemokines, 113, 114
 Monocyte-derived macrophages (MDMs),
 57–60
 Mouse mammary tumor virus (MMTV), 84,
 125, 132 *table*, 140–143
 Murine acquired immune deficiency
 syndrome (MAIDS), 125, 127, 131
 B cell/T cell collaboration in, 133
 cytokines in, 133, 134
 pathogenesis of, 131–133
 protective immunity against, 135
 TCR in, 134, 135
 Murine leukemia virus (MuLV), 127–131, *see*
 also Friend murine leukemia virus
 (FMuLV)
 Murine retroviruses
 endogenous, 126, 127
 infectious, 127–143

N

Nairobi prostitutes, 15
 Natural killer (NK) cells, 115, 116, 310
 Nef protein, 58, 109–112, 216
 The Netherlands, 15
 NF- κ B, 58
 “Noah” (chimpanzee), 2
 Non-syncytium-inducing (NSI) viruses,
 282–284

O, P

Oncoviridae, 159, 160
 p-21 activated kinase (PAK) family, 112
Pan troglodytes schweinfurthii (*Pts*), 2, *see also*
 Chimpanzees
Pan troglodytes troglodytes (*Ptt*), 2–5, 263, *see*
 also Chimpanzees
 Peripheral blood mononuclear cells
 (PBMCs), 54, 60, 116, 193
 Perussis toxin (PTX), 34
 Phorbol myristate acetate (PMA) activation,
 35
 Phospholipase C (PLC), 34, 35

Primary HIV infection (PI), *see also* HIV
 CTL responses in, 217–221
 Primate lentiviruses, 249–270
 HIV and, 2–6
 Protein kinase C (PKC) activation, 35
 Proteoglycans, 41, 42

R

RANTES, 35, 36, 41, 42, 65
 Rauscher MuLV (RMuLV), 139, 140
 Recombinase-activating gene (RAG)
 products, 83
 Retroviruses
 feline, 144–150
 transmission, 125
 Rhesus macaques, *see* Macaques
 RNA viruses, 1

S

Sabaeus monkeys, *see* African green
 monkeys (AGMs)
 Seronegativity, 15, 16
 Seven-transmembrane G protein coupled
 receptors (GPCRs), 35, 36
 Seven-transmembrane TMI-VII domains, 34
 Severe combined immunodeficiency (SCID)
 mice, 139, 199, 221
 Simian acquired immune deficiency
 syndrome (SAIDS), 125, 251
 Simian-human immunodeficiency viruses
 (SHIVs), chimeric, 198, 251, 255
 Simian immunodeficiency virus (SIV), 5, 6,
 37, 198, 240, *see also* headings
 beginning with SIV
 Simian T-cell leukemia virus (STLV), 159, 160
 Single positive (SP) cells, 83–85
 SIVagm, 5, 6, 249, 266, 267, *see also* African
 green monkeys (AGMs)
 cellular immunity in, 269
 humoral immunity in, 268, 269
 immune responses in, 268, 269
 pathogenicity of, 267, 268
 SIVcpz, 2–5, 250
 SIVmac, 249, 251, *see also* Macaques
 clinical manifestations, 251, 252
 CTL responses, 252, 253, 255, 256
 humoral responses, 252
 immune responses in, 252–254
 lymphocytes in, 252
 SIVsm, 5, 249, *see also* Sooty mangabeys (SM)
 lymphocytes in, 257, 258

- viral factors, 256, 257
 - SIVsmDelta B670, 251
 - Sooty mangabeys
 - AIDS and, 256
 - chemokine receptors in, 257
 - humoral immunity, 259, 260
 - immune responses in, 257–262
 - SIV infection in, 256
 - T-cell turnover in, 262
 - Sooty mangabeys (SM), 5, 249, *see also* SIVsm
 - Spleen focus forming virus (SFFV), 135, 136
 - Stem cell factor (SCF), 86
 - Stromal cells, cytokines and, 85–87
 - Syncytium-inducing (SI) viruses, 282–284
- T**
- Tantalus monkeys, *see* African green monkeys (AGMs)
 - Tat protein, 58, 112–116
 - T-cell line adapted (TCLA) strains, 193–196
 - T-cell receptor excision circles (TRECs), 96, 97
 - T-cell receptors, 213, 214
 - in HAM/TSP, 174, 175
 - T-cell receptor α (TCR- α), 83, 96
 - T-cell receptor β (TCR- β), 82, 83, 96
 - T-cell receptor (TCR) repertoire, 79, 95, 96, 214
 - MAIDS and, 134, 135
 - T-cells, 80
 - activation pathways, 111, 112
 - decline, 9
 - extrathymic maturation, 93
 - hierarchical regulation of numbers, 91
 - immune escape, 16, 17
 - immune response, 15
 - intrathymic maturation, 81–83
 - MAIDS and, 133, 134
 - Nef and, 111, 112
 - turnover, 94, 95
 - Thailand, 1, 11
 - Thalidomide, 321
 - T-helper (Th) cells, 2, 64, 65
 - antiviral therapy and, 242
 - CTLs and, 240, 241
 - escape variants, 16
 - HCV and, 242
 - HIV-1 specific, 237–244
 - in HIV infection, 239–244
 - targets of, 240
 - Therapy, *see also* Highly active antiretroviral therapy (HAART)
 - antiretroviral, 317
 - antiviral “cocktails,” 65, 66, 242
 - chemokines and, 42–44
 - cytokine-based, 318–320
 - to decrease HIV replication, 320–325
 - gene, 43, 44
 - immunologic approaches to, 317–325
 - Th cells and, 242
 - Thymocytes
 - maturation, 81–83
 - negative selection, 84, 85
 - positive selection, 83, 84
 - stromal cells and, 85–87
 - Thymopoiesis, 86, 87
 - Thymus, 80
 - functional persistence of, 92, 93
 - in adults, 92–97
 - in children, 92, 93
 - mass, 94–97
 - T-lymphotropic virus type II, *see* HTLV-II
 - TMI-VII domains, 34
 - Transforming growth factor- β (TGF- β), 54, 56, 59, 60
 - Tumor necrosis factor (TNF), 116, 321
 - Tumor necrosis factor- α (TNF- α), 54, 58, 116, 321
- V, W**
- Vaccination, 17–22, 149, 198–202
 - Vervet monkeys, *see* African green monkeys (AGMs)
 - Viral entry, 35–37
 - Viremia, 53, 55
 - immune control in, 237–239
 - Women, HIV infections in, 15